English press releases

Compass Pathways Announces Pricing of Underwritten Offering

LONDON & NEW YORK–(BUSINESS WIRE)– Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today...

Ant Group Extends Partnership with Olympic Tennis Champion Qinwen Zheng as Brand Ambassador

HANGZHOU, China–(BUSINESS WIRE)– Ant Group today announced the extension of its successful partnership with Qinwen Zheng, the rising tennis legend and Olympic gold medalist. This...

Lemonway Unveils Online Onboarding Solution for Marketplaces, Powered by Entrust Identity Verification Solution

PARIS–(BUSINESS WIRE)– Lemonway, a leading European payment institution, proudly announces the launch of Online Onboarding, an innovative solution designed to streamline and enhance the merchant...

European Commission Approves the Extension of the Indication of Palforzia® to the Treatment of Toddlers With Confirmed Peanut Allergy

BAAR, Switzerland–(BUSINESS WIRE)– Stallergenes Greer, a biopharmaceutical company specialising in allergen immunotherapy (AIT), announces that the European Commission (EC) has approved the extension of indication...

ProTek Fiber expands full-fiber connectivity in rural Illinois with Adtran

News summary: Service provider required flexible technology to deliver fast, reliable broadband to 10,000 homes in underserved and unserved areas Adtran’s disaggregated fiber access platform...

Azafaros granted important regulatory designations and clearance by European authorities for global Phase 3 studies, to be initiated in 2025

Clinical Trial Application for global Phase 3 trials with nizubaglustat in GM1/GM2 gangliosidoses and Niemann-Pick Disease Type C approved in multiple European countries, anticipated to...

Quectel Unveils Ultra-Compact 5mm x 5mm x 1.05mm LS550G GNSS Module for Positioning in Low-Power Applications

LAS VEGAS–(BUSINESS WIRE)– Quectel Wireless Solutions, a global IoT solutions provider, is excited to introduce the LS550G, an ultra-compact multi-constellation GNSS module engineered for fast...

Korea Zinc’s Acquisition of Igneo Holdings Sparks Controversy Over 100x Seller Profits

Acquired a fledgling company less than 18 months old for 100 times its initial capital. Acquisition negotiations began just five months after Igneo’s establishment —a...

Merck Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology Portfolio

Reinforces company’s commitment to differentiated solutions that enable faster and more effective drug development HUB’s organoid offering complements company’s cell culture portfolio of media, reagents,...

Science Awards for Allergy 2025: Call for Applications

BAAR, Switzerland–(BUSINESS WIRE)– The Stallergenes Greer Foundation is pleased to announce the launch of the 2025 edition of its Science Awards for Allergy, an initiative...

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is the First and Only Facilitated Subcutaneous Immunoglobulin (fSCIG) Approved in Japan for Agammaglobulinemia and...

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn

TOKYO & MUNICH–(BUSINESS WIRE)– Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab...

Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13

BOSTON–(BUSINESS WIRE)– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P....

Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis

– ALYFTREK™ is approved for patients 6 years and older with at least one responsive mutation, including 31 additional mutations not responsive to other CFTR...

Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants

– Approximately 300 more people with cystic fibrosis in the U.S. are now eligible for a medicine that treats the underlying cause of their disease...